Chief Investment Officer, KIS Capital Partners

Josh Best

Chief Investment Officer

Boutique absolute return fund manager

KIS Capital Partners

KIS Capital Partners is a boutique absolute return fund manager based in Sydney, Australia with an Asia ex Japan trading focus. We believe that an absolute return fund should be risk and performance focused with strong attention to investment differentiation. Absolute return funds should not be asset gatherers. We invest alongside our clients in liquid and transparent markets with a focus on pragmatic and vigilant risk management.

Thematic (Sector/Industry)

<p>At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and which may be disrupted. In the middle of 2016, KIS Research published its in-depth report on Autonomous Vehicles. That paper proved to be well ahead of the curve, with autonomous cars and electric vehicles becoming an important investment theme over the last year. To follow up the success of that report, we have released this one, focusing on a new topic: human longevity. We see human longevity as a huge new investment theme. Whilst its impact on the healthcare system alone will be enormous, we expect its ripples to extend further, washing into the broader economy. Human longevity will create a more productive working age population, extend the retirement age, create new consumer spending patterns amongst the elderly, cause a revamp of the superannuation system, increase unfunded pension liabilities, change life and health insurance premiums, and even alter the way in which fiscal policy is managed, to name a few. In this report we will explore the burgeoning technologies that are seeking to extend healthy life well north of 100 years (NB: there is a section on life hacks that you can be doing today to increase your longevity). If this investment theme is of further interest to you, get in touch with us!</p>

At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and which may be disrupted. In the middle of 2016, KIS Research published its in-depth report on Autonomous Vehicles. That paper proved to be well ahead of the curve, with autonomous cars and electric vehicles becoming an important investment theme over the last year. To follow up the success of that report, we have released this one, focusing on a new topic: human longevity. We see human longevity as a huge new investment theme. Whilst its impact on the healthcare system alone will be enormous, we expect its ripples to extend further, washing into the broader economy. Human longevity will create a more productive working age population, extend the retirement age, create new consumer spending patterns amongst the elderly, cause a revamp of the superannuation system, increase unfunded pension liabilities, change life and health insurance premiums, and even alter the way in which fiscal policy is managed, to name a few. In this report we will explore the burgeoning technologies that are seeking to extend healthy life well north of 100 years (NB: there is a section on life hacks that you can be doing today to increase your longevity). If this investment theme is of further interest to you, get in touch with us!

United States

Aravive, Inc. operates as a biotechnology company. The Company develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive serves patients in the United States.

Trevena, Inc. develops pharmaceutical products. The Company offers discovery and development of agents targeting G-protein coupled receptors and therapies and drugs that treat acute heart failure, acute chronic pain, and depression. Trevena serves customers throughout the United States.

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic, and infectious diseases.

Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS").  The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"),

Aptinyx Inc. operates as a bio-pharmaceutical company. The Company focuses on discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx serves patients in the United States.

Ensysce Biosciences, Inc. operates as a clinical stage biotech company. The Company focuses on stemming the prescription drug abuse epidemic. Ensysce Biosciences serves customers worldwide.

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Bellicum Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel cellular immunotherapies for cancer, tumors, and blood diseases. Bellicum Pharmaceuticals serves patients in the United States.

Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It offer tests for disorders in cardiovascular, hereditary cancer, neurology, pediatrics, and other rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Biosino Bio-Technology & Science, Inc. is a biotechnology company.  The Company develops, manufactures, and markets protein-based in-vitro diagnostic reagents and biochemical drugs.  The Company's diagnostic reagents help diagnose cardiac, helatic, diabetes, inflammation/immunology, and pancreatic related diseases.

Patrys Limited develops therapies for the capture, production, and development of natural human antibodies as therapies for cancer and other diseases.

Algorae Pharmaceuticals Limited operates as a clinical-stage pharmaceutical company. The Company focuses on research and development programs to accelerate patient access to novel drugs and therapies using the latest technologies and scientific innovations. Algorae Pharmaceuticals offers its services worldwide.

Bionomics Limited operates as a biotechnology company, which specializes in the genetics field.  The Company, which is affiliated with a number of research institutions, seeks to develop a variety of genomic, genetic, molecular and cell biology techniques, which they believe will help demonstrate the onset and progression of diseases like epilepsy and breast cancer.

Bioxyne  Limited operates as a biotechnology company.  The Company specializes in the research, development and commercialization of diseases related to chronic obstructive pulmonary disease(COPD).

DorsaVi Ltd. develops and sells wireless sensor movement monitoring systems. The Company's technology is used by the to monitor workplace and sports related injury and pain.

Bharat Immunologicals & Biologicals Corporation Ltd. manufactures and distributes pharmaceutical drugs and vaccines. The Company's primary product is oral polio vaccine (OPV).

Oncimmune Limited develops and commercializes products for the detection of cancerous. It develops autoantibody assay technologies that have the potential to early detection a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test that is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company is based in Nottingham, the United Kingdom.

Celyad Oncology SA is a bio-pharmaceutical company. The Company specialized in CAR-T cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis, such as cancer. Celyad Oncology serves customers worldwide.

Hybrigenics S.A. is a biotechnology and pharmaceutical company. The Company develops therapeutics against cancer as well as develops platforms to identify, validate and inhibit protein interactions.

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Organovo Holdings (ONVO US)

Human Longevity

At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...

KIS Capital Partners

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)